Insiders At Apellis Pharmaceuticals Sold US$7.9m In Stock, Alluding To Potential Weakness
Insiders At Apellis Pharmaceuticals Sold US$7.9m In Stock, Alluding To Potential Weakness
The fact that multiple Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, if numerous insiders are selling, shareholders should investigate more.
Apellis Pharmaceuticals公司（NASDAQ:APLS）的多名內部人士在過去一年大量賣出股票的事實可能引起投資者的關注。分析內部交易時，通常更有價值的是了解內部人員是否在購買，而非是否在出售，後者發出的信息不明確。但是，如果多名內部人員在出售股票，股東應該進行更多調查。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
儘管我們永遠不會建議投資者僅基於公司董事的行動做出決策，但邏輯推斷您應該關注內部人士是否買賣股票。
The Last 12 Months Of Insider Transactions At Apellis Pharmaceuticals
Apellis Pharmaceuticals公司的內部交易在過去一年中進行。
Over the last year, we can see that the biggest insider sale was by the Co-Founder, Cedric Francois, for US$873k worth of shares, at about US$65.00 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$36.00. So it may not shed much light on insider confidence at current levels.
在過去的一年中，我們可以看到聯合創始人Cedric Francois出售了價值87.3萬美元的股票，每股價格約爲65.00美元，是最大的內部交易。雖然我們通常不喜歡看到內部人員出售股票，但如果交易發生在較低價格的情況下，這更令人擔憂。值得欣慰的是，這次出售是在遠高於當前股價36.00美元的價格下進行的，因此可能並沒有太大的關於內部信心的啓示。
In the last year Apellis Pharmaceuticals insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
Apellis Pharmaceuticals公司在過去一年中，其內部人員沒有購買任何公司股票。您可以在下面的圖表中查看過去一年來公司和個人的內部交易情況。單擊下面的圖表，您可以查看每個內部交易的詳細信息！
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜歡購買內部人員正在購買而不是銷售的股票，那麼你可能會喜歡這份免費的公司列表。（提示：它們中的大部分都被忽視了。）
Does Apellis Pharmaceuticals Boast High Insider Ownership?
Apellis Pharmaceuticals公司有高股權內部擁有可能會使公司管理層更加註意股東利益。令人欣慰的是，Apellis Pharmaceuticals的內部人員擁有公司的3.6%股權，價值約爲17200萬美元。這種內部重要持股通常會增加公司由所有股東來運營的機會。
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Apellis Pharmaceuticals insiders own 3.6% of the company, worth about US$172m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
對於普通股東來說，值得檢查公司內部人員持有多少股份。高股權內部擁有通常會使公司管理層更加註意股東利益。值得慶幸的是，Apellis Pharmaceuticals公司的內部人員擁有公司的3.6%股份，價值約爲17200萬美元。這種內部人員的重要持股通常會增加公司由所有股東運營的機會。
What Might The Insider Transactions At Apellis Pharmaceuticals Tell Us?
Apellis Pharmaceuticals公司的內部交易可能會告訴我們什麼？在過去一段時間內，Apellis Pharmaceuticals公司的內部人員沒有進行任何交易，這當然不會對我們造成困擾。儘管我們對Apellis Pharmaceuticals公司高股權內部擁有感到滿意，但我們對股票的出售感到擔憂。因此，這些內部交易可以幫助我們建立一種關於股票的論點，同時也值得了解該公司面臨的風險。例子：我們發現了2個Apellis Pharmaceuticals公司的警示信號，您應該知道。
The fact that there have been no Apellis Pharmaceuticals insider transactions recently certainly doesn't bother us. While we feel good about high insider ownership of Apellis Pharmaceuticals, we can't say the same about the selling of shares. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 2 warning signs for Apellis Pharmaceuticals you should be aware of.
Apellis Pharmaceuticals公司的多名內部人士在過去一年大量賣出股票。當分析內部交易時，要了解內部人員是否在購買股票比是否出售更有價值，因爲後者發出的信息往往不明確。Apellis Pharmaceuticals公司的內部人員沒有購買任何公司股票，這當然不會對我們造成困擾。儘管我們對Apellis Pharmaceuticals公司高股權內部擁有感到滿意，但我們對股票的出售感到擔憂。因此，這些內部交易可以幫助我們建立一種關於股票的論點，同時也值得了解該公司面臨的風險。例子：我們發現了2個Apellis Pharmaceuticals公司的警示信號，您應該知道。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。